A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

David Bonita Biography and Net Worth

Director of Repare Therapeutics

David Bonita, M.D. has served as a member of our board of directors since September 2019. Dr. Bonita is a member of OrbiMed Advisors LLC, an investment firm, where he has held various positions since joining in June 2004. He currently serves on the boards of directors of Tricida, Inc. and Imara Inc. Dr. Bonita previously served on the boards of directors of several other public and private companies, including Ambit Biosciences Corporation, Clementia Pharmaceuticals Inc., Loxo Oncology, Inc., SI-BONE, Inc. and ViewRay Inc.

Prior to joining OrbiMed, he worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. Dr. Bonita has published scientific articles in peer-reviewed journals based on signal transduction research performed at Harvard Medical School.

He received his B.A. in biology from Harvard University and his joint M.D./M.B.A. from Columbia University.

How do I contact David P. Bonita?: The corporate mailing address for Mr. Bonita and other Repare Therapeutics executives is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. Repare Therapeutics can also be reached via phone at 857-412-7018 and via email at [email protected]. Learn More on David P. Bonita's contact information.
Has David P. Bonita been buying or selling shares of Repare Therapeutics?: David P. Bonita has not been actively trading shares of Repare Therapeutics during the past quarter. Most recently, David P. Bonita sold 887 shares of the business's stock in a transaction on Tuesday, September 7th. The shares were sold at an average price of $33.93, for a transaction totalling $30,095.91. Learn More on David P. Bonita's trading history.
Who are Repare Therapeutics' active insiders?: Repare Therapeutics' insider roster includes David Bonita (Director), Thomas Civik (Director), Todd Foley (Director), Ansbert Gadicke (Major Shareholder), Lloyd Segal (CEO), and Michael Zinda (EVP). Learn More on Repare Therapeutics' active insiders.
Are insiders buying or selling shares of Repare Therapeutics?: In the last twelve months, Repare Therapeutics insiders bought shares 2 times. They purchased a total of 1,715,265 shares worth more than $7,479,132.40. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 12,740 shares worth more than $68,485.47. The most recent insider tranaction occured on April, 1st when CEO Lloyd Mitchell Segal sold 2,491 shares worth more than $11,533.33. Insiders at Repare Therapeutics own 28.5% of the company. Learn More about insider trades at Repare Therapeutics.
Information on this page was last updated on 4/1/2024.

David P. Bonita Insider Trading History at Repare Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/7/2021	Sell	887	$33.93	$30,095.91
9/3/2021	Sell	7,197	$34.00	$244,698.00

David P. Bonita Buying and Selling Activity at Repare Therapeutics

Repare Therapeutics Company Overview

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Today's Range

Now: $3.26

$3.09

$3.40

50 Day Range

MA: $5.20

$3.02

$7.20

2 Week Range

Now: $3.26

$2.98

$13.85

Volume

109,320 shs

Average Volume

145,759 shs

Market Capitalization

$120.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Incredible Opportunity to Retire FAST!

From Crypto 101 Media | Ad